Pathway Genomics

Clinical Genomics to Present at 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum

Retrieved on: 
Tuesday, November 10, 2020
Branches of biology, Clinical medicine, Medicine, Cancer, Colorectal cancer, Genomics, Biotechnology, Medical signs, Pathway Genomics, Clinicogenomics

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer.

Key Points: 
  • Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer.
  • Clinical Genomics products span the full spectrum of colorectal cancer testing from screening to post-treatment monitoring.
  • Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management.
  • Investor Relations for Clinical Genomics:

Clinical Genomics Announces Publication of Additional Clinical Data for COLVERA® Recurrence monitoring Blood Test for Colorectal Cancer Patients

Retrieved on: 
Tuesday, September 22, 2020
Clinical medicine, Medicine, RTT, Infectious causes of cancer, DNA, Oncology, Colorectal cancer, Minimal residual disease, Circulating tumor DNA, Cancer, Pathway Genomics, CAPP-Seq

This U.S. population study further reinforces the performance of COLVERA, the breakthrough blood test for the clinical presence of CRC recurrence in patients amenable to curative intent.

Key Points: 
  • This U.S. population study further reinforces the performance of COLVERA, the breakthrough blood test for the clinical presence of CRC recurrence in patients amenable to curative intent.
  • COLVERA therefore represents an important advance over the current standard of care for colorectal cancer surveillance.
  • Clinical Genomics products span the full spectrum of colorectal cancer testing from screening to post-treatment monitoring.
  • COLVERA is the first of its kind blood test to detect circulating tumor DNA for minimal residual disease (MRD) assessment and recurrence monitoring in patients previously diagnosed with colorectal cancer.

Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions

Retrieved on: 
Wednesday, July 24, 2019
Medicine, Clinical medicine, Branches of biology, Medical genetics, RTT, Genetic counseling, Prostate cancer, Genetic testing, Cancer, Prostate cancer screening, Pathway Genomics

Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.

Key Points: 
  • Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.
  • In addition to testing, the Detect programs offer participants post-test genetic counseling to help them understand their test results and make more informed decisions about their health.
  • Some programs also offer follow-up testing to family members of patients with genetic variants associated with disease to better understand their disease risks.
  • The Detect Hereditary Prostate Cancer program provides no-charge genetic testing and counseling for individuals diagnosed with prostate cancers, stage II and above.

ZibdyHealth Integrates Clinical and Genomic Data: Makes Pharmacogenomics Easy to Understand, Simple to Use, and Useful for Everyone

Retrieved on: 
Wednesday, December 5, 2018
Genomics, Pharmacy, Health, Pharmacology, Biology, Pharmacogenomics, Omics, Polypharmacy, Pathway Genomics

Genetic tests and reports are not easy to understand or simple to use for an average person.

Key Points: 
  • Genetic tests and reports are not easy to understand or simple to use for an average person.
  • To make it easy for people to understand this complex information, and democratize genomics, ZibdyHealth has integrated it with the patient's clinical information.
  • "This new integration of genomics with clinical data will make pharmacogenomics more effective for everyone, especially polypharmacy patients,"said Hirdey Bhathal, CEO of ZibdyHealth.
  • "We started by integrating pharmacogenomics, as it is the most validated area of genomics, and we plan further genomic integration."

Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data

Retrieved on: 
Tuesday, October 16, 2018
Genetics, Biology, Applied genetics, Bioinformatics, 23andMe, Coronary artery disease, Genomic counseling, Pathway Genomics

Scientists at the SRTI have developed a smartphone-powered research study that seeks to understand how receiving personal genetic risk information impacts health decisions.

Key Points: 
  • Scientists at the SRTI have developed a smartphone-powered research study that seeks to understand how receiving personal genetic risk information impacts health decisions.
  • The MyGeneRank app allows individuals with genetic data from the consumer genomics company, 23andMe, to obtain an estimated genetic risk score for coronary artery disease (CAD).
  • Surveys and digital health data will be used to determine if this information helped guide decision-making related to lifestyle modification and initiation of medications.
  • For more information on Seqster and how we can bring health to your members, employees or patients, please visit www.seqster.com or follow @Seqster.

Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening

Retrieved on: 
Monday, June 25, 2018
Medicine, Medical genetics, Health, Clinical medicine, In vitro fertilisation, Midwifery, Eugenics, Preimplantation genetic diagnosis, Prenatal sex discernment, Genetic testing, Reproductive health, Pathway Genomics

"By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be have the information they need to make appropriate health decisions when starting a family," said Robert Nussbaum, M.D., chief medical officer of Invitae.

Key Points: 
  • "By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be have the information they need to make appropriate health decisions when starting a family," said Robert Nussbaum, M.D., chief medical officer of Invitae.
  • "We're building the industry's most comprehensive and affordable reproductive health offering, using our world-class expertise to increase access to genetic information when having a family," said Sean George, co-founder and chief executive officer of Invitae.
  • The Invitae Carrier Screen replaces the existing GeneVu carrier screen previously ordered through Good Start Genetics, which was acquired by Invitae in 2017.
  • The test extends the company's reproductive health testing services, which include preimplantation genetic screening (PGS), miscarriage analysis, pre-natal and neonatal testing.

Understanding Health Risks Through Affordable At-Home Genetic Testing

Retrieved on: 
Wednesday, May 23, 2018
Medicine, Medical genetics, Medical tests, Biology, Clinical medicine, Alternatives to animal testing, Genetic testing, Biotechnology, Pathway Genomics, Molecular diagnostics

The company's clinical-grade genetic tests focus on genetic mutations that can cause serious hereditary health conditions like cancer and heart disease.

Key Points: 
  • The company's clinical-grade genetic tests focus on genetic mutations that can cause serious hereditary health conditions like cancer and heart disease.
  • With an understanding of your genetic risk, you can work with your healthcare provider to create a plan to help detect, treat, or prevent the conditions altogether.
  • Color's CLIA-licensed and CAP-accredited lab deploys cutting-edge software engineering, robotics, and Next Generation Sequencing (NGS) technology to drive one of the most affordable and accessible clinical grade genetic testing programs available today.
  • $99
    Hereditary Heart Health Test Analyzes 30 genes commonly associated with inherited heart conditions.